Endocrine Abstracts

Interferon gamma-induced protein 10, a proinflammatory chemokine, has a significant effect in inflammatory diseases. Interferon-inducible protein of 10 kD (IP-10/CXCL10), is a member of the C-X-C chemokine superfamily. It is a potent chemoattractant for activated T lymphocytes and is reported to be involved in various disease states, including atheroma plaque formation, inhibition of tumor angiogenesis and maintenance of podocyte function. However, the involvement of IP-10 in DMT2, especially in its vascular and renal complications, is not thoroughly studied. A study domain with promising potential of the IP-10 influence is its relation with patients with DMT2 with macrovascular complications in the context of disbalanced lipid profile LDL, HDL, Total cholesterol, triglycerides, BMI >30 kg/m², poor Glycaemic control.

Materials. Methods: To elucidate the etiopathological role of IP-10 in DMT2, we measured the concentrations of IP-10/in plasma samples from 130 patients with various degrees of macrovascular complications, and with high level of BMI and poor Glycaemic control and dyslipidemia. We focus our research on measuring of the IP-10/CXCL10 as an inflammatory marker in DM2T and its relation to the above-mentioned complications. IP-10/CXCL10 is related to patients with dyslipidaemia. Patients with higher BMI are potentially associated with increased levels of IP-10/CXCL10. To examine the dependencies between the studied blood test parameters and IP-10/CXCL10 we set up a study including following data: IP-10/CXCL10 plasma levels of 56 men and 74 women with DMT2 were measured by ELISA and compared with dose in 115 healthy control subjects. Some significant differences (t-test) between averages were obtained for all blood test parameters measured for patients with DMT2 related to IP-10CXCL10.

Results: The IP-10/CXCL10 levels were higher in diabetics than in healthy controls (251 pg/ml vs 209 pg/ml p = 0.043). IP-10/CXCL10 were significantly increased in hyperlipidemic men and women as compared to those with normal lipidemic profile, respectively within the group of DMT2 patients. The distribution of the number of the controlled patients in both DMT2 subgroups is not well-balanced, where very often is observed different directions of the levels of such parameters like HbA1c and BMI as compared to lipid panel. All the lab tests are significantly differentiated as related to the introduced groups of DMT2 patients and healthy controls as well as within the groups of DMT2 patients having different referent levels of the blood tests and IP-10. IP-10/CXCL10 is related to patients with high levels of LDL, HDL, Total cholesterol and triglycerides.